Impact News +++ Oatly Publishes Swedish Annual Report for 2025 (GlobeNewswire EN) +++ OATLY Aktie -4,21%

MODERNA Aktie

>MODERNA Aktienkurs

41.53 EUR -4.0% (TradegateBSX)

Ask: 41.59 EUR / 1500 Stück

Bid: 41.495 EUR / 1500 Stück

Tagesumsatz: 21731 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

MODERNA Aktie über LYNX handeln

Intraday

1 Jahr

>MODERNA Performance

1 Woche: -9,9%

1 Monat: -3,1%

3 Monate: +10,2%

6 Monate: +80,4%

1 Jahr: +73,3%

laufendes Jahr: +56,4%

>MODERNA Aktie

Name:

MODERNA INC. DL-,0001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US60770K1079 / A2N9D9

Symbol/ Ticker:

0QF (Frankfurt) / MRNA (NASDAQ)

Kürzel:

FRA:0QF, ETR:0QF, 0QF:GR, NASDAQ:MRNA

Index:

S&P500

Webseite:

https://www.modernatx.com..

Profil:

Moderna, Inc. is a biotechnology company specializing in the research, development, and provision of messenger RNA (mRNA) medicines in the United States, Europe, and internationally. Its primary function centers on creating innovative therapeutics an..
>Volltext..

Marktkapitalisierung:

17881.42 Mio. EUR

Unternehmenswert:

14066.62 Mio. EUR

Umsatz:

1658.5 Mio. EUR

EBITDA:

-2439.12 Mio. EUR

Nettogewinn:

-2407.55 Mio. EUR

Gewinn je Aktie:

-6.2 EUR

Schulden:

1113.34 Mio. EUR

Liquide Mittel:

2214.74 Mio. EUR

Operativer Cashflow:

-1597.93 Mio. EUR

Bargeldquote:

2.92

Umsatzwachstum:

-47.05%

Gewinnwachstum:

30.15%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

MODERNA

Letzte Datenerhebung:

28.04.26

>MODERNA Kennzahlen

Aktien/ Unternehmen:

Aktien: 396.59 Mio. St.

Frei handelbar: 91.54%

Leerverk. Aktien: 15.05%

Rückkaufquote: -0.17%

Mitarbeiter: 4700

Umsatz/Mitarb.: 0.35 Mio. EUR

Analysten:

Analystenrating: Neutral

Kursziel: -12.57%

Bewertung:

KGV: -

KGV lG: -

KUV: 11.07

KBV: 2.35

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: 44.29%

Gewinnmarge: -145.16%

Operative Marge: -158.13%

Managementeffizenz:

Gesamtkaprendite: -21.31%

Eigenkaprendite: -28.87%

>MODERNA Peer Group

Gesundheit, Medizin für Bakterielle- & Pilzinfektionen/ Antibiotika, Lungenerkrankungen & -behandlung/ Asthma, mRNA- Forschung/ Impfstoffe, Onkologie/ Krebs- Behandlung
>Alle Branchen..

>MODERNA Chart & Kurs - NASDAQ

>MODERNA News

27.04.26 - 14:33	TOMI Environmental Solutions, Inc. Sees Strong Interest In Its Solutions at INTERPHEX 2026 (GlobeNewswire EN)
	Company Showcases SteraMist iHP Automation to Industry Giants Including Amgen, Merck, and Moderna; Finalizes Custom Engineering Contract for Proprietary Healthcare System Company Showcases SteraMist iHP Automation to Industry Giants Including Amgen, Merck, and Moderna; Finalizes Custom Engineering Contract for Proprietary Healthcare System...

25.04.26 - 09:54	Curevac: Übernommenes Biotechunternehmen verklagt Moderna wegen Patenten (Manager-Magazin)
	Zahlreiche Biotechunternehmen versuchten zuletzt, sich nachträglich Anteile an den milliardenschweren Einnahmen aus COVID-19-Impfstoffen zu sichern – so auch Curevac. Das im vergangenen Jahr von Biontech übernommene Unternehmen fordert von Moderna Schadensersatz....

24.04.26 - 17:30	Moderna (MRNA) May Report Negative Earnings: Know the Trend Ahead of Next Week′s Release (Zacks)
	Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

22.04.26 - 19:00	European Commission Approves MRNA′s COVID-19-Influenza Combo Shot (Zacks)
	Moderna wins EU approval for its COVID-19-flu combo shot mCombriax, backed by strong phase III data showing superior immune response vs standalone vaccines....

22.04.26 - 17:03	Moderna starts late-stage trial for bird flu vaccine (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

22.04.26 - 01:06	Moderna, Inc.: Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate (Accesswire)
	Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / Apri......

21.04.26 - 17:00	Moderna Receives EU Approval for Influenza and COVID-19 Combination Vaccine for Older Adults (AAStocks)
	Moderna (MRNA.US) said on Tuesday that the European Commission has granted marketing authorization for a combination vaccine indicated for the prevention of influenza and COVID-19 in adults aged 50 and above.(to/s)~AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatically translated by AI, the Chinese versio......

21.04.26 - 16:33	Moderna granted EU nod for combined COVID-19 and flu vaccine (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

21.04.26 - 16:06	Moderna, Inc.: Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting (Accesswire)
	Moderna to host an investor event via webcast on Monday, June 1 at 6:15 PM CDT CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on......

21.04.26 - 15:54	Moderna, Inc.: Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna′s mRNA Combination Vaccine Against Influenza and COVID-19 (Accesswire)
	mCOMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's fourth authorized productmCOMBRIAX will be made available in the European Union, s......

21.04.26 - 13:06	Moderna, Inc.: Moderna to Present at Upcoming Conferences in May 2026 (Accesswire)
	CAMBRIDGE, MA / ACCESS Newswire / April 21, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:BofA Securities 2026 Healthcare Conf......

19.04.26 - 06:37	Sanofi′s Nuvaxovid Shows Superior Tolerability Over Moderna′s MNEXSPIKE In COMPARE Study (AFX)
	PARIS (dpa-AFX) - Sanofi's (SNY, SNYNF,SAN.PA) protein-based COVID-19 vaccine, Nuvaxovid (NVX-CoV2705), demonstrated a significantly better tolerability profile compared to Moderna's latest mRNA v......

17.04.26 - 21:06	Moderna, Inc.: Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting (Accesswire)
	The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor refractory unresectable or metastatic melanoma with PD-L1+ ......

16.04.26 - 18:18	Cómo Anthropic descubrió que Mythos era demasiado peligroso (Bloomberg)
	Los propios expertos de la empresa de IA advirtieron que Mythos podría vulnerar los sistemas que sustentan gran parte de la computación moderna. Bancos y agencias gubernamentales se apresuran a evaluar la amenaza....

15.04.26 - 13:06	Moderna, Inc.: Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026 (Accesswire)
	CAMBRIDGE, MA / ACCESS Newswire / April 15, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, May 1,2026 to report i......

09.04.26 - 07:48	Moderna eyes international markets as growth driver, says Bank of America (Proactive Investors)
	Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

08.04.26 - 16:30	Moderna Is Most Shorted S&P 500 Stock Now. Is It a Contrarian Buy? (Barchart)
	Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...

07.04.26 - 14:06

Life Sciences Ontario Welcomes New Board Members in 2026 Following Annual General Meeting (Business Wire)

TORONTO--(BUSINESS WIRE)--Life Sciences Ontario (LSO) is pleased to announce the appointment of four distinguished leaders to its Board of Directors, following its Annual General Meeting on March 25, 2026. The newly appointed board members are: Amelia Swanson, vice-president, Medtech Canada Dave Smardon, president and CEO, Bioenterprise Canada Leslie Madden, senior director, head of government affairs and policy, Moderna Canada Melody Greaves, executive director and vice-president, government relations, Canadian Nuclear Isotope Council “We are delighted to welcome such highly qualified professionals to the Board,” said Dr. Jason Field, president and CEO, Life Sciences Ontario. “They each bring exceptional experience and a demonstrated ability to drive innovation, shape policy, and build meaningful partnerships. We look forward to working together to advance Ontario's life sciences sector and strengthen its global competitiveness.” During the Annual General Meeting, LSO also presented its 2025 Ann...

07.04.26 - 00:06	Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 (Accesswire)
	CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010......

03.04.26 - 17:48	Top Moderna Shareholders (Investopedia)
	Um den gesamten Artikel unter investopedia.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Am meisten Platz ist zu Hause. - Sprichwort Serbien

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram